ly2456302
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01232439)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Kappa opioid receptorANTAGONIST
OPRK1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 3-fluoro4-(4-((2-(3,5-dimethylphenyl)pyrrolidin-1-yl)methyl)phenoxy)benzamide
- ly2456302
- ly2456302
- ly2456302
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02218775 | Phase 1 | Oct 1, 2014 | Duke University, Yale University |
| NCT01232439 | Phase 1 | Dec 1, 2010 | Eli Lilly |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Eli Lilly | For profit | 1 | 1 | 1 | 2010 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1